The protein peroxiredoxin-4 may be a useful blood marker in the early detection of acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF), a study has found. The finding was described in the article “The overexpression of peroxiredoxin-4 affects the progression of idiopathic pulmonary fibrosis,” which was published…
News
New York cardiopulmonary physical therapist Noah Greenspan has launched the Pulmonary Wellness Foundation (PWF), a nonprofit group that provides free online information on a range of prevalent, rare and ultra-rare pulmonary diseases for those who can’t afford to pay for it. PWF specifically targets patients with pulmonary fibrosis,…
Galapagos NV announced that its Phase 2 PINTA trial, evaluating the safety and effectiveness of oral GLPG1205 in people with idiopathic pulmonary fibrosis (IPF), has completed patient recruitment ahead of schedule. GLPG1205 is a small molecule designed to specifically block the activity of GPR84, a protein that…
Marking a decade of raising funds to battle pulmonary fibrosis (PF), this year’s glitzy and glamorous “Broadway Belts for PFF!” event will be held on Feb. 24 in New York City. Bringing together a host of Broadway stars and other celebrities, the annual evening…
Boehringer Ingelheim has acquired the worldwide exclusive rights to Enleofen‘s interleukin-11 (IL-11) platform, designed for the treatment of fibrotic diseases such as pulmonary fibrosis. This newly established partnership brings together Boehringer Ingelheim’s expertise and substantial pipeline in fibrotic diseases, and Enleofen’s knowledge of IL-11 biology. Enleofen…
Biopharmaceutical company Scholar Rock received $25 million from Gilead Sciences to continue the development of potential therapies to treat the progression of fibrotic diseases, including pulmonary fibrosis (PF). This funding is a milestone payment, based on Scholar Rock’s preclinical studies in animals showing the effectiveness of therapeutic…
Galecto Biotech and PharmAkea, two clinical-stage pharmaceutical companies with robust pipelines in fibrotic diseases and cancer, have merged into a single company. Following the merger, the combined company will maintain the Galecto name, as well as its current senior management team, which includes Hans Schambye as CEO. Galecto,…
By blocking activity of the protein GSK-3 beta, the investigational therapy 9-ING-41 slowed disease progression and improved lung function in mice with pulmonary fibrosis (PF), a study found. The study, “Glycogen Synthase Kinase-3β Inhibition with 9-ING-41 Attenuates the Progression of Pulmonary Fibrosis,” was published in the…
Low daily doses of Esbriet (pirfenidone), less than 1200 mg per day, are equally effective at slowing lung function decline in people with idiopathic pulmonary fibrosis (IPF) as higher daily doses, a real-world analysis found. Lower doses may help to limit therapy…
Use of INOpulse — inhaled nitric oxide — increased physical activity and improved patient-reported outcomes in people with pulmonary fibrosis (PF) who are at risk of pulmonary hypertension (PH), new topline clinical trial data suggest. INOpulse, developed by Bellerophon Therapeutics, is a device that delivers nitric oxide (NO)…
